The effect of rosiglitazone on LRP1 expression and amyloid β uptake in human brain microvascular endothelial cells: A possible role of a low-dose thiazolidinedione for dementia treatment

International Journal of Neuropsychopharmacology

Volumn 15, Issue 1, 2012, Pages 135-142

  Moon, Jae Hoon ^a   Kim, Hyung Jun ^a   Yang, Ae Hee ^a   Kim, Hyun Min ^a   Lee, Byung Wan ^a   Kang, Eun Seok ^a   Lee, Hyun Chul ^a   Cha, Bong Soo ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Alzheimer's disease; amyloid ; blood brain barrier; LRP1; thiazolidinedione

Indexed keywords

AMYLOID BETA PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MESSENGER RNA; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIINFLAMMATORY AGENT; LRP1 PROTEIN, HUMAN; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CELL; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LOW DRUG DOSE; MICROVASCULAR ENDOTHELIAL CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; UPREGULATION; BRAIN; DRUG EFFECTS; ENDOTHELIUM CELL; GENE EXPRESSION; GENETICS; METABOLISM; MICROVASCULATURE; PATHOPHYSIOLOGY; PHYSIOLOGY; PROMOTER REGION; VASCULARIZATION;

AMYLOID BETA-PEPTIDES; ANTI-INFLAMMATORY AGENTS; BLOOD-BRAIN BARRIER; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; GENE EXPRESSION; HUMANS; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-1; MICROVESSELS; NEUROPROTECTIVE AGENTS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; THIAZOLIDINEDIONES;

EID: 84856492410     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145711001611     Document Type: Article

References (22)

1. Akter K, Lanza EA, Martin SA, Myronyuk N, et al. (2011). Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? British Journal of Clinical Pharmacology 71, 365-376.
2. Ballard C, Gauthier S, Corbett A, Brayne C, et al. (2011). Alzheimer's disease. Lancet 377, 1019-1031.
3. Bates KA, Verdile G, Li QX, Ames D, et al. (2009). Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests. Molecular Psychiatry 14, 469-486.
4. Cox PJ, Ryan DA, Hollis FJ, Harris AM, et al. (2000). Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metabolism and Disposition : The Biological Fate of Chemicals 28, 772-780. (Pubitemid 30470827)
5. Deane R, Wu Z, Sagare A, Davis J, et al. (2004). LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43, 333-344. (Pubitemid 39061126)
6. Gauthier A, Vassiliou G, Benoist F, McPherson R (2003). Adipocyte low density lipoprotein receptor-related protein gene expression and function is regulated by peroxisome proliferator-activated receptor gamma. Journal of Biological Chemistry 278, 11945-11953. (Pubitemid 36800168)
7. Geldmacher DS, Fritsch T, McClendon MJ, Landreth G (2011). A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. Archives of Neurology 68, 45-50.
8. Gold M, Alderton C, Zvartau-Hind M, Egginton S, et al. (2010). Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease : results from a randomized, double-blind, placebo-controlled phase III study. Dementia and Geriatric Cognitive Disorders 30, 131-146.
9. Goto JJ, Tanzi RE (2002). The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's A beta generation : development of a cell-based model system. Journal of Molecular Neuroscience 19, 37-41. (Pubitemid 35013332)
10. Hauser S, Adelmant G, Sarraf P, Wright HM, et al. (2000). Degradation of the peroxisome proliferatoractivated receptor gamma is linked to liganddependent activation. Journal of Biological Chemistry 275, 18527-18533. (Pubitemid 30414814)
11. Herz J, Strickland DK (2001). LRP: a multifunctional scavenger and signaling receptor. Journal of Clinical Investigation 108, 779-784. (Pubitemid 32880284)
12. Landreth G, Jiang Q, Mandrekar S, Heneka M (2008). PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics 5, 481-489. (Pubitemid 351952487)
13. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, et al. (2010). Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 330, 1774.
14. Monro OR, Mackic JB, Yamada S, Segal MB, et al. (2002). Substitution at codon 22 reduces clearance of Alzheimer's amyloid-beta peptide from the cerebrospinal fluid and prevents its transport from the central nervous system into blood. Neurobiology of Aging 23, 405-412. (Pubitemid 34312024)
15. Niemi M, Backman JT, Granfors M, Laitila J, et al. (2003). Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia 46, 1319-1323. (Pubitemid 37297200)
16. Riederer P, Bartl J, Laux G, Grunblatt E (2011). Diabetes type II : a risk factor for depression-Parkinson-Alzheimer? Neurotoxicity Research 19, 253-265.
17. Sagare A, Deane R, Bell RD, Johnson B, et al. (2007). Clearance of amyloid-beta by circulating lipoprotein receptors. Nature Medicine 13, 1029-1031. (Pubitemid 47517512)
18. Shibata M, Yamada S, Kumar SR, Calero M, et al. (2000). Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. Journal of Clinical Investigation 106, 1489-1499. (Pubitemid 32038587)
19. Shinohara M, Sato N, Kurinami H, Takeuchi D, et al. (2010). Reduction of brain beta-amyloid (Abeta) by fluvastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, through increase in degradation of amyloid precursor protein C-terminal fragments (APP-CTFs) and Abeta clearance. Journal of Biological Chemistry 285, 22091-22102.
20. Ueno M, Nakagawa T, Wu B, Onodera M, et al. (2010). Transporters in the brain endothelial barrier. Current Medicinal Chemistry 17, 1125-1138.
21. Wirths O, Multhaup G, Bayer TA (2004). A modified betaamyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide-the first step of a fatal cascade. Journal of Neurochemistry 91, 513-520. (Pubitemid 39431147)
22. Zlokovic BV, Deane R, Sagare AP, Bell RD, et al. (2010). Low-density lipoprotein receptor-related protein-1 : a serial clearance homeostatic mechanism controlling Alzheimer's amyloid beta-peptide elimination from the brain. Journal of Neurochemistry 115, 1077-1089.